Last reviewed · How we verify
CMAB008
CMAB008 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
At a glance
| Generic name | CMAB008 |
|---|---|
| Also known as | infliximab |
| Sponsor | Shanghai Biomabs Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a monoclonal antibody developed by Shanghai Biomabs, CMAB008 is designed to modulate immune responses or block tumor survival pathways. The exact molecular target requires confirmation, but the drug is in Phase 3 development, suggesting clinical efficacy has been demonstrated in earlier trials for its intended oncology indication.
Approved indications
Common side effects
Key clinical trials
- Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients (PHASE4)
- The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety (PHASE1)
- CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CMAB008 CI brief — competitive landscape report
- CMAB008 updates RSS · CI watch RSS
- Shanghai Biomabs Pharmaceutical Co., Ltd. portfolio CI